Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke

Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

ABSTRACT

Objective: To assess the evidence for the use of diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) in the diagnosis of patients with acute ischemic stroke.

Methods: We systematically analyzed the literature from 1966 to January 2008 to address the diagnostic and prognostic value of DWI and PWI.

Results and Recommendations: DWI is established as useful and should be considered more useful than noncontrast CT for the diagnosis of acute ischemic stroke within 12 hours of symptom onset. DWI should be performed for the most accurate diagnosis of acute ischemic stroke (Level A); however, the sensitivity of DWI for the diagnosis of ischemic stroke in a general sample of patients with possible acute stroke is not perfect. The diagnostic accuracy of DWI in evaluating cerebral hemorrhage is outside the scope of this guideline. On the basis of Class II and III evidence, baseline DWI volumes probably predict baseline stroke severity in anterior territory stroke (Level B) but possibly do not in vertebrobasilar artery territory stroke (Level C). Baseline DWI lesion volumes probably predict (final) infarct volumes (Level B) and possibly predict early and late clinical outcome measures (Level C). Baseline PWI volumes predict to a lesser degree the baseline stroke severity compared with DWI (Level C). There is insufficient evidence to support or refute the value of PWI in diagnosing acute ischemic stroke (Level U). *Neurology® 2010;75:177-185

GLOSSARY

ADC = apparent diffusion coefficient; ASPECTS = Alberta Stroke Program Early CT Score; CBF = cerebral blood flow; CI = confidence interval; DWI = diffusion-weighted imaging; ICH = intracerebral hemorrhage; MR = magnetic resonance; NIHSS = National Institute of Health Stroke Scale; PWI = perfusion-weighted imaging; tPA = tissue plasminogen activator.

Stroke is the third leading cause of death and the leading cause of permanent disability and disability-adjusted loss of independent life-years in Western countries.1 Presently, the only specific, approved therapy for acute ischemic stroke is IV tissue plasminogen activator (tPA) given within 4.5 hours.2–6 tPA use has been limited due to the short treatment window, concerns about the limitations of CT-based diagnosis, and fear of hemorrhagic risks.

Noncontrast CT is the current diagnostic standard for acute stroke due to its wide availability and presumed near-perfect sensitivity for acute intracerebral hemorrhage (ICH),7,8 the most important differential diagnosis to ischemic stroke. For ischemic infarction, a number of early signs have been described9 and formalized CT scores have been developed.10 The sensitivity of CT in acute ischemic stroke varies, depending on the imaging features of infarction, examination time from clinical onset, study population, and other variables. Sensitivity estimates range from 12% to 92%, with an overall estimate of 40%–60% for the 6-hour time window.11 A post hoc analysis of the CT data from the National Institute of Neurological Disorders and Stroke tPA study yielded a 31% sensitivity for early infarct signs.12 Despite the fact...

From the National Institutes of Neurological Disorders and Stroke (P.D.S., S.W.), NIH, Bethesda, MD; Department of Neurology (P.D.S.), University of Erlangen, Germany; Departments of Radiology (R.N.B.) and Neurology (J.A.D.), University of Pennsylvania, Philadelphia; Department of Neurology (L.R.C.), Beth Israel Deaconess Medical Center, Boston, MA; Department of Radiology (R.R.E.), Northwestern University, Evanston, IL; Division of Neurology (C.J.), Toronto General Hospital, Canada; Department of Neurology (C.S.K.), Georgetown University, Washington, DC; Columbia University (J.P.M.), New York, NY; Department of Neurology (M.S.), University of South Florida, Tampa; and Department of Radiology (A.G.S.), MGH, Boston, MA.

Appendices e-1–e-6 and references e1–e7 are available on the Neurology® Web site at www.neurology.org.

Approved by the Therapeutics and Technology Assessment Subcommittee on November 15, 2008; by the Practice Committee on August 4, 2009; and by the AAN Board of Directors on April 25, 2010.

Disclosure: Author disclosures are provided at the end of the article.
that CT accuracy in acute stroke has never been established by formal assessment of the evidence relative to an independent standard, CT has become the de facto diagnostic standard.

As noncontrast CT has limited sensitivity for the diagnosis of ischemic stroke in the initial hours, improved accuracy of stroke diagnosis is necessary for the development and application of optimal thrombolytic and other stroke therapy. New MRI techniques such as diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) add another dimension to diagnostic imaging and have the potential to improve the diagnostic yield while being practical and feasible.

DWI measures the net movement of water in tissue due to random (Brownian) molecular motion of water and shows hyperintense ischemic tissue due to random (Brownian) molecular motion of water and shows hyperintense ischemic tissue compared with necrosis and cytotoxic edema. Decreases in the ADC and increased signal on DWI studies in many instances represent irreversible ischemia. To differentiate acute from subacute or older lesions (T2 shine-through), DWI is used in conjunction with T2-weighted images and ADC maps.

PWI allows the measurement of capillary perfusion. The method most commonly used in clinical practice and research is the dynamic susceptibility contrast-enhanced technique, in which paramagnetic contrast agent is injected as an IV bolus and the signal change is tracked by susceptibility-weighted, T2*-weighted magnetic resonance (MR) sequences. Relative cerebrovascular hemodynamic measures reflecting cerebral blood volume, mean transit time, time to peak, and cerebral blood flow (CBF) can be derived from the MR signal intensity-over-time curve in a semiquantitative fashion. Parameter maps display the area of critical reduced perfusion.

Although studies have overcome the usual logistical obstacles to the emergency use of MRI, doubts remain regarding the feasibility, practicality, and validity of stroke MRI in the clinical setting. As there is no true imaging gold standard for acute ischemic stroke that has been established by comparison with neuropathologic findings, the reference diagnosis of ischemic stroke in most MRI studies is established using a follow-up lesion on CT or conventional MR images consistent with the clinical syndrome and a comprehensive diagnostic workup.

We sought to answer the following questions regarding the accuracy, sensitivity, and specificity of MRI use in acute ischemic stroke:

1. Are DWI and PWI sensitive and specific in the diagnosis of acute ischemic stroke (compared to concurrent imaging with other techniques, established by follow-up imaging, clinical follow-up, and final discharge diagnosis)?
2. Does the volume of the DWI or PWI abnormality predict initial clinical severity, final infarct size, and late clinical outcome?

We addressed these questions solely from the standpoint of diagnostic accuracy. In clinical practice, whether MRI or CT should be performed depends on additional factors that are outside the scope of this assessment. For the second question, the term predict was used instead of correlate. Correlate is a generic term for a measure of association or a specific technique for a measure of the strength of association between continuous variables. Because we reviewed evidence on the basis of both the correlation between continuous variables and the association with dichotomous outcomes, the more generic term “predict” was used in formulating this question.

**DESCRIPTION OF THE ANALYTIC PROCESS**

A panel of neurologists, neuroradiologists, and radiologists was assembled. The panel performed a literature search through January 2008 in the following databases: Medline (starting 1966), Embase (starting 1974), Biosis (starting 1969), and Sci (starting 1990). The exact keyword search is available in appendix e-1 on the Neurology® Web site at www.neurology.org.

We identified 492 abstracts for question 1 (DWI), 213 for question 1 (PWI), and 210 for question 2. Two panel members reviewed each abstract. Exclusion criteria were as follows: 1) unrelated to acute ischemic stroke <12 hours (question 1) or <24 hours (question 2) after symptom onset or unrelated to questions; 2) unrelated to DWI or PWI (i.e., CT, T2-weighted imaging, Xe-CT, PET, SPECT); 3) case report or case series with n <15; 4) review article; 5) letter to the editor or editorial; 6) involving pediatric patients or nonhuman subjects; or 7) nonclinical (e.g., technique development). The eligible publications of each pair were discussed with the whole panel to produce a final list of articles for each question.

We chose a time window of 12 hours for question 1 because most treatment studies for acute stroke have an inclusion window of <12 hours. DWI and PWI have a high diagnostic accuracy within the first hours, and effective treatment of acute stroke is negatively correlated with time from symptom onset.
Studies that included patients in a time window exceeding 12 hours were considered for inclusion if a subset of patients <12 hours was reported or the numbers for such a subset could be extracted. For question 2, we chose a time window of 24 hours and a sample size of 30 or more for inclusion. Furthermore, we excluded studies in which any patients received thrombolytic therapy so as not to confound the prognostic value of DWI and PWI with regard to the natural disease course.

Recently reported large open series,22,23 phase II and III randomized, placebo-controlled trials of MRI-guided IV thrombolysis in acute stroke (DIAS, DEDAS, DIAS-2, EPITHET)24-27 are a case in point. These trials selected patients for inclusion up to 9 hours from stroke onset on the basis of a qualitative MRI penumbral pattern. For this assessment, only the placebo groups of these trials would be eligible and helpful in judging diagnostic accuracy (question 1) or predictive value for baseline clinical status and clinical or structural outcome (question 2). No separate imaging data are available for any of these studies yet; in EPITHET, only summary data and the subgroups with PWI/DWI mismatch are presented.

Evidence was classified using a 4-tier classification scheme for diagnostic (question 1) and prognostic (question 2) articles (appendix e-2 and e-3), and recommendations were based on these levels of evidence (appendix e-4). If more than one publication from identical groups entered data extraction, the manuscripts were assessed for the same patients being used in different analyses. In this case, the publication with the highest class of evidence and patient number was included. After the selection process, panel members discussed potentially relevant publications that could change the level of recommendation. These studies were included or excluded by consensus.

**ANALYSIS OF EVIDENCE** Question 1: Are DWI and PWI sensitive and specific in the diagnosis of acute ischemic stroke (compared to concurrent imaging with other techniques, established by follow-up imaging, clinical follow-up, and final discharge diagnosis)? We identified 62 studies fulfilling the inclusion criteria. Twenty-six were excluded due to patient overlap with other studies of the same investigator groups. Of the remaining 36 articles, 32 are not discussed further because they consisted of Class III (n = 4) and IV (n = 28) evidence.

For DWI, there was 1 Class I28 and 3 Class II studies7,13,29; all PWI studies were Class IV. The Class I study assessed the accuracy of MRI (DWI and gradient echo scans) vs CT in 356 consecutive patients presenting to a hospital emergency department over an 18-month period in whom the emergency physician diagnosed possible acute stroke.28 Therefore, ischemic strokes, nonischemic strokes, and stroke mimics were included. Patients with the suspected diagnosis of acute stroke were imaged a median of 34 minutes earlier by MRI than CT. Two neuroradiologists and 2 stroke neurologists independently interpreted all scans, blinded to clinical information and CT-DWI pairings. In the subset of 221 patients scanned within 12 hours of onset, the majority of readers correctly diagnosed acute ischemic stroke by MRI more often than by CT (94 vs 22, p < 0.0001). The odds ratio and its 95% confidence interval (CI) of the difference in the proportions was 25 (8–79), indicating an effect size sufficiently large for this single study to justify a Level A recommendation. A similar direction and magnitude of difference were also seen in the subset of 90 patients scanned within 3 hours of onset. Relative to the final hospital discharge diagnosis (based on follow-up imaging and clinical syndrome), the sensitivity, specificity, and accuracy of DWI were 77%, 96%, and 86%, and of CT were 16%, 97%, and 55%. These sensitivities are lower than in other series, which may indicate vulnerability to selection bias, as they lacked a cohort of nonstroke controls and underrepresented milder strokes that were seen in this sample (median National Institute of Health Stroke Scale [NIHSS] score was 4). The performance of baseline imaging in predicting final diagnosis is limited by the fact that all imaging findings were available in the hospital medical record to clinicians who made the discharge diagnosis.

A Class II study prospectively evaluated 50 patients with ischemic stroke and 4 patients with TIA.13 Patients were randomized to receive MRI or CT within 6 hours of stroke onset. The independent diagnosis of stroke was established by the clinical course and follow-up CT or MRI. Five stroke experts and 4 residents independently judged the images. They were blinded to the patients’ symptoms and signs but were aware that the cohort was an ischemic stroke population. The sensitivity of infarct detection by the experts was significantly better when based on DWI (91%) than CT (61%), as was the accuracy: DWI (91%), CT (61%). Interrater variability of lesion detection was also significantly better for DWI (κ = 0.84) than for CT (κ = 0.51). DWI had good interrater homogeneity and better sensitivity and accuracy than CT, even if the raters had limited experience.

The discrimination of ischemic from hemorrhagic stroke was studied in a Class II prospective multicenter study of 62 patients with ICH or ischemic stroke who were assessed within 6 hours (mean 3 hours 23 minutes) with DWI, T2-weighted imaging, and T2*-weighted imaging.7 Baseline CT,
follow-up imaging, and clinical course were used to establish the diagnosis of ischemic stroke and ICH. Three blinded raters independently rated all scans. All ischemic strokes and ICHs were correctly identified. Because the aim of this study was to evaluate whether MRI with DWI could differentiate ischemic stroke from ICH within the first 6 hours, the spectrum of patients and controls was narrow. This study is pertinent to the diagnostic strength of CT and MRI for both ischemic and hemorrhagic stroke; however, the latter is outside the parameters of this report and is not addressed further.

A final Class II prospective study of 100 patients compared DWI and CT with a blinded image analysis.29 CT was performed first within 6 hours of symptom onset, followed by DWI within 7 hours of symptom onset. Because 39 patients received tPA, the study was excluded for question 2. Five blinded readers applied the Alberta Stroke Program Early CT Score (ASPECTS)10 for both CT and DWI and validated the scores by follow-up imaging. The ASPECTS is a formalized CT-derived score used to evaluate the degree of ischemic changes in the middle cerebral artery territory. DWI and CT ASPECTS were positively related (p < 0.001). Of CT scans with ASPECTS of 8–10, 81% had DWI ASPECTS of 8–10. Early CT changes were found in 66% of patients (CI 56–75), and DWI abnormalities were found in 81% of patients (CI 72–88; nonsignificant). However, the median CT ASPECTS was 9 and the median DWI ASPECTS was 8, indicating lesions are more conspicuous with the latter method.

Table 1 summarizes the results of the 4 Class I and II studies that address question 1.

Table 1 Class I and II studies for question 1: Is DWI sensitive and specific in the diagnosis of acute ischemic stroke?

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Objectives, design</th>
<th>Results</th>
<th>Class of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chalela et al.28 (2007)</td>
<td>Diagnostic accuracy of DWI (and GRE) compared to CT and final clinical diagnosis for acute stroke (ischemic and hemorrhagic). Total sample = 356; 221 &lt;12 hours. Majority opinion of blinded, independent reads by panel of 4 experts. Representative and broad spectrum of patients with clinical suspicion of stroke by emergency physician (actual diagnosis: ischemic stroke, TIA, primary hemorrhage, not cerebrovascular). MRI obtained earlier than CT by 34 minutes.</td>
<td>MRI superior to CT for acute ischemic stroke detection &lt;12 hours from onset: OR (95% CI) = 25 (8–79); CT: sensitivity 16%, specificity 97%, accuracy 55%; MRI: sensitivity 78%, specificity 96%, accuracy 86%</td>
<td>I</td>
</tr>
<tr>
<td>Fiebach et al.13 (2002)</td>
<td>Randomized comparison of CT and DWI in ischemic stroke &lt;6 hours. CT before DWI by 9 minutes.</td>
<td>Sensitivity experts: CT 61% (range 52%–70%); DWI 91% (range 88%–94%); sensitivity novices: CT 48% (range 32%–64%); DWI 81% (range 78%–86%)</td>
<td>II</td>
</tr>
<tr>
<td>Fiebach et al.7 (2004)</td>
<td>Diagnostic accuracy of T2, T2*, DWI to discriminate ischemic stroke from ICH.</td>
<td>Sensitivity: 100% (95% CI 97.1%–100%); specificity, PPV, NPV, accuracy: 100%</td>
<td>II</td>
</tr>
<tr>
<td>Barber et al.29 (2005)</td>
<td>Diagnostic accuracy of CT and DWI &lt;6 (7) hours by ASPECTS score. CT always before DWI.</td>
<td>Sensitivity: CT: 66% (CI 56–75); DWI: 81% (CI 72–88)</td>
<td>II</td>
</tr>
</tbody>
</table>

Abbreviations: ASPECTS = Alberta Stroke Program Early CT Score; CI = confidence interval; DWI = diffusion-weighted imaging; GRE = gradient echo; NPV = negative predictive value; OR = odds ratio; PPV = positive predictive value.

Conclusions. DWI is established as superior to CT for the diagnosis of acute ischemic stroke within 12 hours of symptom onset (1 Class I study with large effect). The diagnostic accuracy of DWI in the evaluation of hemorrhagic stroke is outside the scope of this review.

Question 2: Does the volume of the DWI or PWI abnormality predict initial clinical severity, final infarct size, and late clinical outcome? We identified 8 studies fulfilling the inclusion criteria. Of these, 4 Class IV studies assessed only the correlation of baseline DWI and PWI lesion volume with chronic lesion volume.30–33 1 Class II study assessed only the correlation of baseline DWI and PWI lesion volume with clinical outcome,34 and 2 Class II studies and 1 Class III study assessed both clinical and morphologic outcome.35–37 None of the identified studies compared CT with MRI in predicting these outcomes.

One Class II study investigated whether DWI is useful for clinicoradiologic correlation of posterior-circulation ischemia within 24 hours of symptom onset and whether NIHSS score correlates with lesion volumes in patients with posterior-circulation stroke.34 Using imaging and clinical criteria, 115 of 631 patients (18%) had symptoms of posterior-circulation ischemia. Of these 115, 40 patients fulfilled the inclusion criteria with regard to time window and available imaging data. An acute lesion corresponding to the patient’s symptoms was detected in all 40 patients on DWI but in only 16 patients on T2-weighted imaging. Acute lesion volume did not correlate with NIHSS score (n = 40; rho = 0.3; p = 0.06). The authors conclude that DWI has a higher diagnostic accuracy than T2-weighted imaging in patients with acute posterior-circulation...
strokes and suggest that DWI lesion volumes do not correlate with NIHSS score because the NIHSS score may be less valid in posterior-circulation than in anterior-circulation stroke symptoms.

Another Class II study assessed 50 patients diagnosed with acute ischemic middle cerebral artery territory stroke (<24-hour duration) with DWI. Thirty-four patients had volumes measured by T2-weighted imaging chronically (median 7.5 weeks). Acute lesion volumes correlated with the acute (r = 0.56–0.61, p < 0.0001) and chronic (r = 0.63, p < 0.0001) NIHSS and with chronic lesion volumes (r = 0.84–0.90, p < 0.0001). The correlation of acute DWI lesion volume with the chronic Barthel Index was moderate (r = −0.33, p = 0.034).

A final Class II study examined DWI and PWI characteristics in a neuroprotective double-blind placebo-controlled study involving patients with acute ischemic stroke. Patients with acute ischemic stroke symptom onset 24 hours or less before the start of treatment, NIHSS scores of 5 or higher, and lesions of 1 to 120 mL in cerebral gray matter by DWI were enrolled. Of the 100 patients enrolled, 81 had interpretable MR measurements. Baseline DWI and PWI lesion volumes correlated with baseline NIHSS scores (r = 0.64 and r = 0.49, both p < 0.001). Baseline DWI volume also correlated with follow-up lesion volume at 12 weeks (r = 0.79, p < 0.001). The authors conclude that significant correlations between lesion volumes and clinical measures were found, replicating values reported in the literature for smaller case series, and suggest that this relationship supports the role of DWI as a clinically meaningful surrogate marker in stroke clinical trials.

The aim of the Class III study was to investigate whether the relationship between acute NIHSS scores and acute stroke volume (as determined by acute DWI and PWI) differs between right-sided and left-sided stroke. This difference may be important if a low NIHSS score is used to exclude patients with right-hemisphere stroke from clinical trials or established treatments. A total of 153 patients were retrospectively assessed with MRI within 24 hours of stroke onset. There were correlations between the acute NIHSS scores and acute DWI lesion volumes (r = 0.48 right, r = 0.58 left, p < 0.0001) and between acute NIHSS scores and PWI hypoperfusion volumes (r = 0.62 right, r = 0.60 left, p < 0.0001). However, multiple linear regression analysis revealed a lower acute NIHSS score on the right side compared to the left when adjusted for stroke volume on follow-up T2 imaging (p = 0.03). The authors concluded that patients with right hemispheric stroke may have a lower NIHSS despite substantial acute stroke volume defined by DWI and PWI, and these imaging modalities may be more useful than the NIHSS in identifying patients who may be eligible for acute stroke protocols.

A combination of the baseline NIHSS score, time from stroke onset to DWI, and the baseline lesion volume on DWI was an independent predictor of clinical outcome (3-month Barthel Index) in a logistic regression model. The model was externally validated with a 77% sensitivity and 88% specificity. A similar retrospective study of 63 patients investigated whether the baseline DWI lesion volume was an independent predictor of functional outcome. In both instances, the derivation and validation groups were very small.

Table 2 summarizes the results of the 3 Class II studies that address question 2.

### Conclusions

Baseline DWI volume probably predicts baseline clinical stroke severity and final lesion

---

### Table 2

**Class II studies for question 2: Does the volume of the DWI or PWI abnormality correlate with initial clinical severity, final infarct size, and late clinical outcome?**

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Objectives, design</th>
<th>Results</th>
<th>Class of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linfante et al. (2001)</td>
<td>Prognosis of DWI lesion volume and clinical outcome measured with NIHSS in patients with posterior circulation ischemia within 24 hours of symptom onset.</td>
<td>DWI lesion volume did not correlate with NIHSS (r = 0.3, p = 0.06)</td>
<td>II</td>
</tr>
<tr>
<td>Lovblad et al. (1997)</td>
<td>Prognosis of DWI lesion volume and 1) clinical measures during acute and chronic stages after MCA territory stroke; 2) chronic lesion volume.</td>
<td>DWI lesion volumes correlated with the acute (r = 0.56–0.61, p &lt; 0.0001) and chronic (r = 0.63, p &lt; 0.0001) NIHSS with moderate correlation with chronic Barthel Index (r = −0.33, p = 0.034). DWI lesion volume correlated with chronic lesion volumes (r = 0.84–0.90, p &lt; 0.0001).</td>
<td>II</td>
</tr>
<tr>
<td>Warach et al. (2000)</td>
<td>Correlation of DWI and PWI lesion volume within 24 hours of symptom onset with acute stroke severity measured with NIHSS. Prognosis of baseline DWI volume and chronic lesion volume.</td>
<td>Baseline DWI and PWI lesion volumes significantly correlated with baseline NIHSS scores (r = 0.64 and r = 0.49, both p &lt; 0.001). Baseline DWI volume correlated with follow-up lesion volume at 12 weeks (r = 0.79, p &lt; 0.001).</td>
<td>II</td>
</tr>
</tbody>
</table>

Abbreviations: DWI – diffusion-weighted imaging; MCA – middle cerebral artery; NIHSS – National Institute of Health Stroke Scale; PWI – perfusion-weighted imaging.
volume in anterior-circulation stroke syndromes (multiple Class II studies) and is possibly accurate in predicting clinical outcome as measured by the NIHSS and Barthel Index (1 Class II study). Baseline DWI volume possibly does not predict the baseline NIHSS score in posterior-circulation stroke syndromes (1 Class II study). Baseline PWI volume possibly predicts baseline clinical stroke severity (1 Class II study).

RECOMMENDATIONS

1. DWI should be considered superior to noncontrast CT scan for the diagnosis of acute ischemic stroke in patients presenting within 12 hours of symptom onset (Level A).
2. There is insufficient evidence to support or refute the value of PWI in diagnosing acute ischemic stroke (Level U).
3. Baseline DWI volume should be considered useful in predicting baseline clinical stroke severity and final lesion volume in anterior-circulation stroke syndromes (Level B).
4. Baseline DWI volume may be considered not useful in predicting baseline NIHSS score in posterior-circulation stroke syndromes (Level C).
5. Baseline DWI volume may be considered useful in predicting clinical outcome as measured by the NIHSS and Barthel Index (Level C).
6. Baseline PWI volume may be considered useful in predicting baseline clinical stroke severity (Level C).

CLINICAL CONTEXT

In patients presenting with acute neurologic impairment, noncontrast CT imaging is used to evaluate for infarct and to exclude hemorrhage and other structural lesions that may mimic stroke. The evidence from our report demonstrates that DWI is accurate and superior to CT for the diagnosis of acute ischemic stroke\(^7,13,28,29\) relative to clinical and imaging outcomes. However, in clinical practice, the availability and cost of imaging modalities and the requirements of medical management enter into the decision about which test to perform in the acute period.

The true sensitivity of DWI for the diagnosis of ischemic stroke is not 100% and is probably closer to 80%–90% in a general sample of patients presenting for emergency evaluation of possible stroke. Many of the initial case series and small CT comparative studies reported a near-100% sensitivity for DWI in the hyperacute stage of stroke\(^40,e1,e2\) in highly selected subsets of patients. Increasingly, however, cases of DWI-negative stroke were reported.\(^45\) False-negative DWI in ischemic stroke may be attributable to mild (small) strokes, brainstem location, and the earliest times from onset, and may become less frequent as imaging technology continues to improve.

DWI-positive scans in TIA are common. According to the literature, acute ischemic DWI lesions are present in 40.1% of patients with the clinical diagnosis of a TIA (10 studies, 234/584 patients), a finding that correlates with symptom duration.\(^44,e5\) Only one of the studies involved DWI performed within 24 hours of symptom onset.\(^46\) A recent study estimated the epidemiologic impact of DWI-based diagnosis would result in reduced annual TIA incidence (33%) and increased stroke incidence (7%) in the United States.\(^47\)

RECOMMENDATIONS FOR FUTURE RESEARCH

1. Prospective, well-designed studies on the diagnostic utility of PWI in acute stroke are needed.
2. Hypoperfusion remains a key pathophysiologic mechanism in stroke. However, it is not known if absolute quantification of CBF at any one moment in time is sufficient for diagnosis or prediction of tissue outcome. If the predictive value of such hemodynamic measures can be validated, semiquantitative or qualitative assessment rather than quantitative techniques (e.g., \(^15\)O-PET scanning) may suffice. There are also newer techniques of PWI on the horizon that provide more quantitative parameters. Which current and which future approaches have superior diagnostic and prognostic utility should be investigated, or a consensus to permit consistent and definitive studies on the use of PWI in acute stroke should be reached.
3. Integration of clinical and laboratory data with DWI in combination with MRA-derived and PWI-derived parameters toward the goal of improving diagnostic utility and prediction of patient outcome and tissue fate should be investigated.
4. The role of DWI-derived and PWI-derived measures as therapeutic selection criteria and as markers of treatment response requires continued study. These promising approaches toward expanding the treatment indications for acute stroke will need to be validated.
5. Further investigation is required to establish the predictive value of DWI-derived lesion volumes within the first hours from onset and the potential added value of PWI measures, as well as to address cost-benefit issues in appropriate medicoeconomic studies.

DISCLOSURE

Dr. Schellinger has served/serves on scientific advisory boards for Boehringer Ingelheim, ImRx Therapeutics, Photothera, Cerevast, and CoAxi, Inc.; has served/serves on speakers’ bureaus for and received funding for economic studies.
travel and speaker honoraria from Boehringer Ingelheim, Sanofi, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Inc., Solvay Pharmaceuticals, Inc., and GlasscockSmithKline; serves on editorial boards of Stroke and European Neurology; receives royalties from the publication of NeuroIntervene (Springer, 2008) and received royalties from the publication of Stroke MRI (Steenkopf, 2004); has served as a consultant for CoAxia, Inc., Photothera, Cerevast, ImaRx, and Boehringer Ingelheim; and has provided expert testimony, affidavits, and acted as a witness or consultant in legal proceedings. Dr. Bryan serves as an Associate Editor of Radiology, on the editorial boards of Magnetic Resonance in Medicine and Contemporary Diagnostic Radiology, and on the editorial executive committee of Academic Radiology, has received research support from Wyeth and the NIH (NOl-HC-95178 [Sub Contract PI] and NOl-WH-4-4221 [Sub Contract PI]); and estimates that 40% of his clinical effort is spent performing CT and 40% is spent performing MRI. Dr. Caplan serves on scientific advisory boards for Boehringer Ingelheim, Genentech, Inc., LifeCycle Pharma A/S, ReNeuron, Novovision, Inc., NeuroLogica Corporation, and Avaris Pharmaceuticals; serves as a consultant to Micromedics, AstraZeneca, Bayer Schering Pharma, Takeda Pharmaceutical Company Limited, Co-Axia, Inc., Millennium Pharmaceuticals, Inc., Jones & Davis L.L.P., and Novo Nordisk; has served on a speakers’ bureau for Orsuka Pharmaceutical Co., Ltd.; serves as Co-editor of Review in Neurological Diseases and on the editorial board of Archives of Neurology; and receives royalties from the publication of Blueprints in Neurology, 2nd ed. (Lippincott Williams & Wilkins, 2006), Brain Embolism (Informa Healthcare, 2006), Case Studies in Stroke: Common and Uncommon Presentations (Cambridge University Press, 2006), Intracranial Atherosclerosis (Wiley-Blackwell, 2008), Uncommon Causes of Stroke, 2nd ed. (Cambridge University Press, 2008), and Caplan’s Stroke: A Clinical Approach, 4th ed. (Elsevier, 2009). Dr. Detre serves on a scientific advisory board for Pittsburgh NMR Center; serves as an Associate Editor of the Journal of Neuroimaging; serves as a consultant for Pfizer Inc.; receives research support from Wyeth, AstraZeneca, Pfizer Inc, the National Science Foundation and from the NIH (R01 MH080729 [PWI], K24 NS058386 [PWI], P30 NS048839 [PWI], T32 NS054575 [PWI], R01 NS060653 [Co-I], R01 NS005752 [Co-I], P41 RR023045 [PWI], R24 HD050836 [PWI], R24 HD050838 [Co-I], R01 NS057400 [Co-I], R01 DK085615 [Co-I], R01 AG034682 [Co-I], R21 DA025882 [Co-I], R01 HL102119 [Co-I], R03 DA027098 [Co-I], R24 HD050836 [Co-I]); is an inventor on a patent re: ASC Perfusion MRI and receives royalties from the University of Pennsylvania for its licensure; and has acted as a witness or consultant in legal proceedings. Dr. Edelman serves as an Associate Editor for Investigative Radiology; has received research support from Siemens Healthcare; and holds a provisional patent re: non-contrast MR angiography and receives license fee payments from Siemens Healthcare. Dr. Jaigobin has received speaker honoraria from sanofi-aventis and Boehringer Ingelheim. Dr. Kidwell serves on the editorial boards of Neurocritical Care Journal, the Journal of Neuroimaging, and Stroke Research and Treatment; has served as a consultant for Embrella Cardiovascular, Inc.; and receives research support from Baxter International Inc., and the NIH (NINDS P50 NS04378 [Co-I] and NINDS U54 NS057104 [PWI]). Dr. Mohr serves on scientific advisory boards for Mitsubishi Tanabe Pharma Corporation and Schering-Plough Corp.; serves on the editorial board of Cerebrovascular Diseases and as Chief Editor of Stroke; receives royalties from the publication of Stroke: Pathophysiology, Diagnosis, and Management 4th ed. (Churchill Livingstone, 2004); serves as a consultant for Schering-Plough Corp.; and has given expert testimony on PFO and unruptured aneurysms. Dr. Sloan serves on the editorial boards of the Journal of Neuroimaging, Stroke, and the Journal of Stroke and Cerebrovascular Diseases; holds financial interest in Boehringer Ingelheim, PDL BioPharma, Inc., Terumo Neurovascular Monitoring, NCME, and Bayer Schering Pharma; has received research support from ImaRx Therapeutics, Inc., Guidant, Cordis, Bard Peripheral Vascular, Inc., Abbott, Boston Scientific, and the NIH/NINDS; estimates that <10% of his clinical effort is spent on transcranial Doppler; and has given expert testimony in a legal proceeding related to this manuscript. Dr. Sorensen serves on scientific advisory boards for Olea Medical, Siemens Healthcare, Genentech, Inc., Lantheus Medical Imaging, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited/Millennium Pharmaceuticals, Inc., AstraZeneca, the NIH, and Bayer Schering Pharma; has received funding for travel from the NIH, Siemens Healthcare, and Genentech, Inc.; serves as a Section Editor for Stroke and on the editorial boards of the Journal of Clinical Oncology and The Oncologist; has served as a consultant for Mitsubishi Tanabe Pharma Corporation, AstraZeneca, Genentech, Inc., Novartis, Lantheus Medical Imaging, and Bayer Schering Pharma; holds patents re: Method for evaluating novel, stroke treatments using a tissue risk map, Imaging system for obtaining quantitative perfusion indices, Delay-compensated calculation of tissue blood flow, High-flow oxygen delivery system and methods of use thereof, and Magnetic resonance spatial risk map for tissue outcome prediction; receives royalty from the publication of Cerebral MR Perfusion Imaging: Principles and Current Applications (Thieme, 2000); estimates that 10% of his clinical effort is spent on MRI; has received research support from Schering-Plough Corp., AstraZeneca, Exelixis, Genentech, Inc., Novartis, Takeda Pharmaceutical Company Limited/Millennium Pharmaceuticals, Inc., Surface Logix Inc., Siemens Healthcare, the NIH (NINDS R01NS058477, NINDS R01NS063925, NINDS R21NS061119, NCICAI37254, and NCRR), and from Aarhus University; receives royalty and license fee payments from Bayer Schering Pharma; holds stock options in EPiX Pharmaceuticals, Inc.; and has given expert testimony in legal proceedings. Dr. Warach serves on the editorial boards of the Journal of Cerebral Blood Flow and Metabolism, Stroke, The Lancet Neurology, and the International Journal of Stroke; and is an employee of NIH, receiving research support exclusively from the Division of Intramural Research of NIH, which includes collaboration agreements with General Electric and Olea Medical.

DISCLAIMER
This statement is provided as an educational service of the American Academy of Neurology. It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved. The clinical context section is made available in order to place the evidence-based guideline(s) into perspective with current practice habits and challenges. No formal practice recommendations should be inferred.

CONFLICT OF INTEREST
The American Academy of Neurology is committed to producing independent, critical and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least three AAN committees, a network of neurologists, Neurology® peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at www.aan.com.

Received August 6, 2009. Accepted in final form April 25, 2010.

REFERENCES

18. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion


14. Schellinger PD, Fiebach JB, Hacke W. Imaging-based de-

13. Fiebach JB, Schellinger PD, Jansen O, et al. CT and


11. von Kummer R, Bozzao L, Manelfe C, eds. Early CT Di-

10. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity


5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with

4. The National Institute of Neurological Disorders and


2. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


1147–1153.

141–150.

58:234–237.

1711.

1670–1674.

33. Wittsack HJ, Ritzl A, Fink GR, et al. MR imaging in acute


31. Karonen JO, Ostergaard L, Vainio P, et al. Diffusion and


24. Davis SM, Donnan GA, Parsons MW, et al. Effects of


22. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


18. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion


14. Schellinger PD, Fiebach JB, Hacke W. Imaging-based de-

13. Fiebach JB, Schellinger PD, Jansen O, et al. CT and


11. von Kummer R, Bozzao L, Manelfe C, eds. Early CT Di-

10. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity


5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with

4. The National Institute of Neurological Disorders and


2. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


1147–1153.

141–150.

58:234–237.

1711.

1670–1674.

33. Wittsack HJ, Ritzl A, Fink GR, et al. MR imaging in acute


31. Karonen JO, Ostergaard L, Vainio P, et al. Diffusion and


24. Davis SM, Donnan GA, Parsons MW, et al. Effects of


22. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


18. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion


14. Schellinger PD, Fiebach JB, Hacke W. Imaging-based de-

13. Fiebach JB, Schellinger PD, Jansen O, et al. CT and


11. von Kummer R, Bozzao L, Manelfe C, eds. Early CT Di-

10. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity


5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with

4. The National Institute of Neurological Disorders and


2. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


1147–1153.

1670–1674.

33. Wittsack HJ, Ritzl A, Fink GR, et al. MR imaging in acute


31. Karonen JO, Ostergaard L, Vainio P, et al. Diffusion and


24. Davis SM, Donnan GA, Parsons MW, et al. Effects of


22. Albers GW, Thijs VN, Wechsler L, et al. Magnetic reso-


18. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion


